Verus Financial Partners Exits Position in Bristol-Myers Squibb Co (BMY)

Bristol-Myers Squibb Co (BMY) : Verus Financial Partners has sold out all of its stake in Bristol-Myers Squibb Co during the most recent quarter, according to the disclosure filed by the company on Oct 13, 2016 with the SEC. The investment management company has sold out 2,961 shares of Bristol-Myers Squibb Co which is valued at $148,761.

Other Hedge Funds, Including , Howland Capital Management boosted its stake in BMY in the latest quarter, The investment management firm added 1,000 additional shares and now holds a total of 39,272 shares of Bristol-Myers Squibb Co which is valued at $1,973,025. Bristol-Myers Squibb Co makes up approx 0.19% of Howland Capital Management’s portfolio.Capital Asset Advisory Services boosted its stake in BMY in the latest quarter, The investment management firm added 310 additional shares and now holds a total of 5,363 shares of Bristol-Myers Squibb Co which is valued at $267,131. Bristol-Myers Squibb Co makes up approx 0.37% of Capital Asset Advisory Services’s portfolio.Naples Global Advisors boosted its stake in BMY in the latest quarter, The investment management firm added 4,000 additional shares and now holds a total of 19,086 shares of Bristol-Myers Squibb Co which is valued at $950,674. Bristol-Myers Squibb Co makes up approx 0.37% of Naples Global Advisors’s portfolio.Hefty Wealth Partners boosted its stake in BMY in the latest quarter, The investment management firm added 1,109 additional shares and now holds a total of 1,196 shares of Bristol-Myers Squibb Co which is valued at $65,529. Bristol-Myers Squibb Co makes up approx 0.05% of Hefty Wealth Partners’s portfolio.Curbstone Financial Management Corp boosted its stake in BMY in the latest quarter, The investment management firm added 84 additional shares and now holds a total of 12,888 shares of Bristol-Myers Squibb Co which is valued at $706,134. Bristol-Myers Squibb Co makes up approx 0.23% of Curbstone Financial Management Corp’s portfolio.

Bristol-Myers Squibb Co closed down -0.26 points or -0.52% at $49.55 with 2,45,32,533 shares getting traded on Tuesday. Post opening the session at $49.67, the shares hit an intraday low of $49.5 and an intraday high of $50.23 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Bristol-Myers Squibb Co reported $0.69 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $0.66. The company had revenue of $4881.00 million for the quarter, compared to analysts expectations of $4657.63 million. The company’s revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.53 EPS.

Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Shares were Reiterated by Barclays on Sep 9, 2016 to “Equal Weight” and Lowered the Price Target to $ 65 from a previous price target of $75 .Bristol-Myers Squibb Co was Downgraded by Berenberg to ” Hold” on Aug 11, 2016. Credit Suisse Downgraded Bristol-Myers Squibb Co on Aug 8, 2016 to ” Neutral”, Price Target of the shares are set at $63.

Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.

Leave a Reply

Bristol-Myers Squibb Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Bristol-Myers Squibb Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.